Acadian Asset Management
ACRS icon

Acadian Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Acadian Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68M Buy
1,641,472
+101,681
+7% +$453K 0.01% 639
2026
Q1 		$5.77M Sell
1,539,791
-582,608
-27% -$1.97M 0.01% 672
2025
Q4 		$6.38M Sell
2,122,399
-204,620
-9% -$517K 0.01% 594
2025
Q3 		$4.42M Sell
2,327,019
-106,831
-4% -$186K 0.01% 676
2025
Q2 		$3.45M Buy
2,433,850
+238,659
+11% +$323K 0.01% 681
2025
Q1 		$3.35M Buy
2,195,191
+451,044
+26% +$962K 0.01% 614
2024
Q4 		$4.32M Sell
1,744,147
-334,140
-16% -$831K 0.01% 560
2024
Q3 		$2.39M Buy
2,078,287
+164,838
+9% +$202K 0.01% 694
2024
Q2 		$2.1M Sell
1,913,449
-221,918
-10% -$261K 0.01% 746
2024
Q1 		$2.65M Sell
2,135,367
-216,040
-9% -$258K 0.01% 597
2023
Q4 		$2.47M Buy
+2,351,407
New +$7.17M 0.01% 620
2021
Q1 		– Sell
-85,362
Closed -$551K – 2034
2020
Q4 		$551K Sell
85,362
-108,834
-56% -$459K ﹤0.01% 1204
2020
Q3 		$499K Buy
194,196
+99,363
+105% +$222K ﹤0.01% 1126
2020
Q2 		$153K Buy
94,833
+76,683
+422% +$103K ﹤0.01% 1583
2020
Q1 		$19K Buy
+18,150
New +$24.7K ﹤0.01% 1651
2019
Q4 		– Sell
-238,234
Closed -$257K – 1820
2019
Q3 		$257K Buy
+238,234
New +$338K ﹤0.01% 1254

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Acadian Asset Management's ACRS Position: Q2 2026 in Review

Acadian Asset Management increased its Aclaris Therapeutics (ACRS) stake by 6.6% in Q2 2026, buying an estimated $453K and bringing the position to 1,641,472 shares worth $8.68M. The position accounts for 0.01% of the portfolio, ranked #639.

Acadian Asset Management first reported a position in ACRS in Q3 2019 and has held it in 16 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Acadian Asset Management held 1,641,472 shares of Aclaris Therapeutics worth $8.68M as of Q2 2026.
  • Acadian Asset Management bought 101,681 Aclaris Therapeutics shares in Q2 2026, an estimated $453K.
  • Aclaris Therapeutics made up 0.01% of Acadian Asset Management's portfolio in Q2 2026, its #639 holding.
  • Acadian Asset Management first reported a position in Aclaris Therapeutics in Q3 2019 and has held it in 16 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.